Last reviewed · How we verify
Viramune
At a glance
| Generic name | Viramune |
|---|---|
| Sponsor | Boehringer Ingelheim |
| Target | Gag-Pol polyprotein, Pol polyprotein, Reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Human immunodeficiency virus infection
Common side effects
- Asymptomatic transaminase elevations (AST or ALT >5X ULN)
- Symptomatic hepatic events
- Grade 1 and 2 rash
- Liver enzyme abnormalities (AST, ALT, GGT)
- GGT elevations
Serious adverse events
- Grade 3 and 4 rash
- Hepatic failure
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Hypersensitivity reactions
- Hepatitis
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Early Infant HIV Treatment in Botswana (PHASE2, PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission (PHASE1, PHASE2)
- Population Pharmacokinetics of Antiretroviral in Children
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Viramune CI brief — competitive landscape report
- Viramune updates RSS · CI watch RSS
- Boehringer Ingelheim portfolio CI